CC-42344
| Program | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
Influenza
CC-42344 (Influenza A PB2 Inhibitor) |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
We are developing CC-42344, a novel PB2 inhibitor, for the treatment of influenza. CC-42344 binds to a highly conserved PB2 site of influenza polymerase complex (PB1: PB2: PA) and exhibits a novel mechanism of action. CC-42344 has shown excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu resistant strains, and has favorable pharmacokinetic profiles. CC-42344 is currently in preclinical development and we expect to initiate a Phase 1 study of CC-42344 in the fourth quarter of 2018.